Skip to main content
$7.35 -$1.66 (-18.4%)

04:00 PM EST on 01/15/21

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: No stars

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Current Price $7.35 Mkt Cap $35.8M
Open $8.86 P/E Ratio 0.00
Prev. Close $7.35 Div. (Yield) $0.00 (0.0%)
Daily Range $7.15 - $9.02 Volume 1,040,795
52-Wk Range $3.12 - $19.25 Avg. Daily Vol. 655,325

Caps

How do you think NASDAQ:CYCC will perform against the market?

Add Stock to CAPS Watchlist

All Players

71 Outperform
9 Underperform
 

All-Star Players

8 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CYCC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (95.74)
Submitted January 03, 2016

My God, is the SEAMLESS trial still running? This pointless excursion began all the way back at the beginning of 2011 and is still lumbering along despite failing an interim futility analysis in December 2014. That's right! The trial already failed.… More

zzlangerhans (95.74)
Submitted February 19, 2015

In the last few months, lots of weak biopharmas took huge hits on negative catalysts and their share prices seemed to gravitate towards the 50 cent level with market caps at about half of cash on hand. I owned substantial chunks of almost all of them… More

NASDAQ:CYCC VS S&P 500 (SPY)

Fools bullish on NASDAQ:CYCC are also bullish on:

Fools bearish on NASDAQ:CYCC are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CYCC.

Recs

0
Member Avatar oscillation (81.38) Submitted: 6/1/2015 1:40:33 AM : Outperform Start Price: $8.64 NASDAQ:CYCC Score: -92.17

nev

Recs

0
Member Avatar UnstableEnabled (< 20) Submitted: 12/21/2013 3:30:17 AM : Outperform Start Price: $44.94 NASDAQ:CYCC Score: -189.61

A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.

It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.

Sorely depressed, any good new will cause the stock to surge upward.

Recs

0
Member Avatar toegar2000 (37.98) Submitted: 3/2/2013 10:25:20 AM : Outperform Start Price: $64.19 NASDAQ:CYCC Score: -236.11

Looks good IMO

Leaderboard

Find the members with the highest scoring picks in CYCC.

Score Leader

BravoBevo

BravoBevo (99.98) Score: +1,220.77

Put on a coat before answering the door. If it's someone you know, let them know you just got home; for everyone else, tell them you're leaving.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BravoBevo 99.98 3/10/2020 Outperform 5Y $0.50 +1,370.00% +34.42% +1,335.58 0 Comment
portefeuille2 99.33 4/29/2019 Outperform 5Y $0.68 +973.62% +28.00% +945.62 0 Comment
Momentum21 86.89 3/1/2018 Outperform 5Y $1.52 +382.25% +38.56% +343.69 0 Comment
longtermgrowth09 < 20 8/3/2010 Underperform 5Y $137.26 -94.65% +234.01% +328.66 0 Comment
mrtofoo 30.48 1/7/2008 Underperform 5Y $425.66 -98.27% +178.12% +276.39 0 Comment
MotleyMK 51.60 7/20/2017 Outperform 5Y $1.73 +324.86% +52.26% +272.60 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. VisionThing < 20 7/19/2017 Outperform 1Y $1.76 +317.38% +52.21% +265.17 0 Comment
imrhh < 20 5/7/2007 Underperform 3M $637.27 -98.85% +163.25% +262.10 2 Comments
bluebare 31.08 12/7/2012 Underperform 5Y $75.63 -90.28% +164.54% +254.82 0 Comment
klaracat 31.00 10/22/2012 Underperform 5Y $60.93 -87.94% +162.45% +250.39 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CYCC.